Workflow access, outcomes-based reimbursement, and care delivery control reshape AI health competition

By DripPublished

The gist

HealthTech value is shifting from standalone software to embedded distribution, reimbursement-backed workflows, and platform-controlled care delivery.

This week’s developments

Embedded Channels Are Becoming the New AI Moat

Doximity and OneMedNet show the same structural shift: AI value is moving from standalone products to embedded distribution channels that already sit inside clinical workflows and data flows. Doximity now reaches more than 190 health systems and has placed Doximity Ask and Doximity Scribe directly into Epic at NewYork-Presbyterian, Columbia, and Weill Cornell, while also exposing access through its clinical-intelligence API layer. OneMedNet extended the data-side version of that model on Nov. 9, 2026, through its 13th channel partnership, enabling an AI company to resell de-identified U.S. multimodal healthcare data from more than 2,300 sites.

The pattern is broader than distribution alone. Hologen and Sysmex’s Saibogen venture is designed to add predictive analytics to Sysmex hematology analyzers without new instruments, reagents, or patient samples. Oura’s Nov. 10, 2026 acquisition of Counsel for $625 million aims to route wearable data into medical guidance, and Wolters Kluwer’s Nov. 13, 2026 acquisition of AgileMD for up to $100 million brings guideline execution and surveillance into UpToDate and EHR workflows. For operators, adoption risk drops when AI arrives through Epic, analyzers, cloud platforms, or wearables. For vendors and investors, the defensible edge is shifting to workflow placement, data-routing rights, and trusted interfaces, not model quality alone.

Where should we build to own workflow and data distribution?

If you operate in this industry

  • AI wins when it rides existing workflows, not when it asks for new ones.
  • Prioritize embedded AI partnerships and workflow-native buys; standalone tools will face slower adoption and easier displacement.

Sources

If you sell into this industry

  • Distribution and data access are becoming the real moat in HealthTech AI.
  • Shift roadmap and GTM toward embedded integrations, channel partnerships, and data-routing rights; model quality alone won't close deals.

Sources

If you invest in this industry

  • Value is migrating to platform owners with workflow and data control.
  • Favor companies with embedded channels and durable access rights; point AI vendors without distribution look increasingly fragile.

Sources

CMS Ties Remote Monitoring Payment to Measurable Clinical Gains

CMS finalized 2027 Medicare payment for remote patient monitoring, remote therapeutic monitoring, and 14 software-based diagnostic analyses while tightening the rules: RTM is limited to established patients, RPM/RTM generally require a separately billable initiating visit, and the direct-employment requirement for monitoring staff was pushed to 2029. CMS also preserved the 2-15 day supply-code pathway, signaling that near-term value may come less from long-duration chronic programs than from short monitoring episodes tied to transitions, acute exacerbations, and post-acute recovery.

That payment structure now collides with outcome accountability. The 2026 ACCESS Model withholds roughly half of chronic-care payment until end-of-period reconciliation and pays in full only when at least half of aligned beneficiaries improve on measures such as blood pressure, HbA1c, weight, pain, function, PHQ-9, or GAD-7. Meanwhile, home-care demand is widening: UPMC’s home rehab pilot and new funding point to post-acute growth, Baptist Health is scaling hospital-at-home, and Mayo Clinic reported just 8 escalations among 165 home-treated pyelonephritis patients, with no in-program deaths.

The shift from reimbursement plumbing to measurable outcomes is now the next test. Platforms that already unified RPM, RTM, and billing will need auditable performance data layered on top; standalone monitoring tools will be harder to defend unless they can show they move the measures CMS is now paying against.

How do we prove outcomes to win reimbursement and market share?

If you operate in this industry

  • Monitoring wins only if it proves measurable clinical improvement.
  • Shift from billing-first RPM/RTM to outcome-linked workflows; add auditable measures or risk being commoditized by platforms that can.

Sources

If you sell into this industry

  • Outcome proof is now the product, not just device or workflow coverage.
  • Build clinical analytics, reconciliation, and measure reporting into the core offer; standalone monitoring tools will struggle to justify spend.

Sources

If you invest in this industry

  • Capital will favor platforms that can tie monitoring to outcomes.
  • Underwrite to evidence and workflow integration, not code coverage alone; point solutions without measurable lift face margin and multiple pressure.

Sources

AI Diagnostics Move From Clearance to Billing Infrastructure

CMS this week put Medicare payment pathways around digital diagnostics, but not through a single AI fee schedule: reimbursement still depends on benefit category, HCPCS/CPT coding, and whether the service is “reasonable and necessary.” That matters because it moves AI diagnostics closer to routine purchasing and billing, even as most products still need separate coding and coverage work. For outpatient software, payment can now be concrete rather than theoretical, with prior examples cited at roughly $128.90 per use for Eko’s SENSORA and about $136 per assessment for MyoVista Insights in 2026. Hospital technologies can also access NTAP at the lesser of 65% of technology cost or 65% of costs above the MS-DRG payment.

The Nov. 15–16, 2026 FDA clearances sharpen the commercialization signal. Eko Health’s Low EF AI was cleared to help clinicians detect LVEF at or below 40%, backed by training on more than 100,000 paired ECG-echocardiogram records and a prospective multisite study of nearly 3,500 subjects. Caption Health’s Caption Guidance was cleared to help non-specialists acquire diagnostic-quality cardiac ultrasound images, and an AI cardiac MRI analysis platform was also approved. The competitive edge is shifting to vendors that pair clearance with coding strategy, workflow integration, and proof of throughput or accuracy gains; the bottleneck is billing readiness and local coverage, not FDA risk alone.

How should vendors adapt to win reimbursement, not just clearance?

If you operate in this industry

  • AI diagnostics are now a billing game, not just a clearance game.
  • Prioritize coding, coverage, and workflow proof; FDA alone won’t drive adoption if local reimbursement and throughput gains aren’t clear.

Sources

If you sell into this industry

  • Clearance is table stakes; reimbursement readiness is the moat.
  • Build HCPCS/CPT strategy, coverage evidence, and billing support into the product and GTM, or rivals will win on deployability.

Sources

If you invest in this industry

  • Reimbursement unlocks real revenue, but only for vendors ready to bill.
  • Favor companies with coding, coverage, and workflow traction; clearance-only stories still face slow monetization and local adoption risk.

Sources

Oura’s Counsel Deal Pushes Platforms Into Care Delivery

Oura’s November 10 agreement to buy Counsel Health for $625 million in cash is the clearest sign that the platform story is now moving from adjacent features into intervention rights. The deal adds a chat-based medical interface, licensed physicians, and the clinical operations to turn ring data into physician review, lab orders, prescriptions, referrals, and preventive or acute care pathways. That shifts Oura’s model from selling insight subscriptions around sleep, recovery, and activity to attaching care delivery and enterprise distribution through Counsel’s employer, health plan, and health system relationships.

The same “measure, interpret, intervene” logic is now showing up across consumer and enterprise stacks. Samsung and OpenAI expanded U.S. health integration through b.well, combining Samsung Health signals with longitudinal records, prescriptions, labs, and histories for use cases like test-result interpretation and appointment prep; b.well’s network spans more than 2.2 million providers and 320 health plans, labs, and other sources. On the enterprise side, R1’s November 12 launch of six Phare OS modules extended AI from isolated RCM tasks into a connected operating layer across authorization, utilization management, documentation integrity, audits, denials, and recovery. After last week’s platform-breadth wave, the procurement bar is now shifting from “does it work?” to “can it close the loop without new handoffs?”

How do platforms capture care delivery rights before competitors do?

If you operate in this industry

  • Care delivery is becoming the moat, not just the data layer.
  • If you only surface insights, you risk disintermediation; build or buy closed-loop care workflows before platforms own the patient relationship.

Sources

If you sell into this industry

  • Buyers now want platforms that can act, not just analyze.
  • Shift roadmap and GTM toward workflow closure, clinical ops, and integrations; point features alone will lose to bundled platform deals.

Sources

If you invest in this industry

  • Value is moving to platforms that control intervention, not dashboards.
  • Favor companies with care delivery rights and distribution; standalone insight tools face margin and multiple compression as bundling accelerates.

Sources

Stay ahead in HealthTech

Get the weekly HealthTech brief in your inbox — the developments, what they mean by vantage, and what to do next.